An update from Vivani Medical ( (VANI) ) is now available. Vivani Medical is advancing its innovative GLP-1 implant technology to address ...

"Our preclinical successes with TGR-63 and IGC-1C, along with the identification of IGC-1A as a potential GLP-1 agonist, ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Terns Pharmaceuticals, Inc. ( (TERN) ) has released its Q3 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc.

With us today is OptimizeRx's Chief Executive Officer, William Febbo. He is joined by Chief Financial Officer, Ed Stelmakh; President, Steve Silvestro; General Counsel, Marion Odense-Ford; and Senior ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Also, U.S. Q3 nonfarm productivity rose +2.2% q/q, missing the +2.6% q/q consensus, while Q3 unit labor costs increased +1.9% q/q, stronger than expectations ... (BEP), ADS (WMS), Plains All American ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication that the market for GLP-1 drugs could likely be a lot bigger. Based on data ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...